markets.businessinsider.com
Eli Lilly announces results from VIVID-2 study
Long-term results matter because they report whether an IL‑23 inhibitor (Omvoh) maintained clinical and endoscopic improvements through two years for people with moderate-to-severe Crohn’s disease, including some with prior biologic failure.
That’s relevant for treatment planning and expectations about durability and safety of a newer biologic.
Adults with moderate-to-severe Crohn’s disease, especially those considering or currently on IL‑23 therapies or with prior biologic failure; IBD clinicians and researchers tracking new biologic data.
What To Know
Eli Lilly reported two-year results from the VIVID-2 open-label extension in moderately to severely active Crohn’s disease for Omvoh (an anti–IL-23p19 therapy).
The announcement summarizes observed-case and modified non-responder imputation analyses showing maintenance and gain of clinical remission and endoscopic response/remission over two years, and states the long-term safety profile was generally consistent with prior data. Data will be presented at the Crohn’s and Colitis Congress.
This is a company report of long-term extension results for Omvoh in Crohn’s disease (patients previously in VIVID-1 continued into VIVID-2). The release gives percentages for maintained or gained clinical and endoscopic outcomes at two years and notes serious adverse events and discontinuations during year two.
It does not provide full study tables, detailed denominators, statistical testing, or peer-reviewed publication text in this item.
If you want details: look for the Crohn’s & Colitis Congress presentation or a full company clinical study report/publication to see patient numbers, exact definitions, comprehensive safety data, and analysis methods (the article references both observed-case and modified non-responder imputation analyses).
This Business Insider markets article summarizes a company announcement; the full data are being presented at a professional congress. Company press summaries are useful for initial signals but should be confirmed by the full congress presentation, peer‑reviewed publication, or independent analyses before changing care decisions.
